Gene Therapy: review time and acceptance speed
ISSN 0969-7128 · ISSN 1476-5462 · Springer Nature · Biochemistry, Genetics and Molecular Biology
Half of the articles Gene Therapy accepted in 2025 were accepted within 169 days of submission (n = 71); the middle half took 134–251 days.
Accepted articles only · dates deposited by the publisher in PubMed · data as of Sep 15, 2026
How long does Gene Therapy take to accept a paper?
| Year | Articles (n) | 25th pct | Median | 75th pct | 90th pct | Accepted <14 days | Have a revised date |
|---|---|---|---|---|---|---|---|
| 2025 | 71 | 134 | 169 | 251 | — | 0.0% | 100% |
| 2024 | 53 | 121 | 174 | 234 | — | 0.0% | 100% |
| 2023 | 50 | 119 | 168 | 235 | — | 0.0% | 100% |
| 2022 | 62 | 114 | 156 | 237 | — | 0.0% | 100% |
| 2021 | 85 | 121 | 169 | 227 | — | 0.0% | 99% |
| 2020 | 88 | 111 | 157 | 227 | — | 0.0% | 99% |
- 2026: not shown yet — a year is reported once late-indexed articles have arrived (at least 180 days after it ends).
Distribution in 2025
Show as a table
| Days | Articles | Share |
|---|---|---|
| 0–29 | 2 | 2.8% |
| 30–59 | 1 | 1.4% |
| 60–89 | 3 | 4.2% |
| 90–119 | 7 | 9.9% |
| 120–149 | 12 | 16.9% |
| 150–179 | 12 | 16.9% |
| 180–209 | 11 | 15.5% |
| 210–239 | 4 | 5.6% |
| 240–269 | 7 | 9.9% |
| 270–299 | 2 | 2.8% |
| 300–329 | 4 | 5.6% |
| 330–359 | 2 | 2.8% |
| 360+ | 4 | 5.6% |
From acceptance to online publication
After acceptance, half of the 2025 articles appeared online within 14 days (middle half 11–21 days, n = 71).
From submission to online publication, the median was 198 days (middle half 149–269 days, n = 71).
Read these numbers carefully
- These times describe articles the journal accepted. Rejected manuscripts never appear in public data, so they cannot tell you how long a rejection takes.
- Dates are the ones the publisher deposited with PubMed. Some publishers record the date a revised manuscript arrived as the submission date, which makes review look faster.
- Invited articles and special issues can move faster than regular submissions.
Open access status and publishing fees
Subscription or hybrid (not determined). Listed APC: about $3,790 (as reported by OpenAlex).
No institutional payments for this journal are recorded in OpenAPC.
Many journals waive or reduce fees for authors from eligible countries or institutions with publishing agreements — check with the journal and your library.
Integrity and indexing signals
Facts from public records, shown without judgement. See the methodology for why each can be worth a closer look.
| Listed in DOAJ | No |
|---|---|
| Articles indexed for MEDLINE in 2025 | Yes |
| Retractions | 0 retracted articles among 322 added to PubMed in 2021–2025 (0.00 per 1,000), per the Retraction Watch Database. |
| Accepted within 14 days of submission | 0.0% of 2025 articles |
| Publication volume | 66 articles added to PubMed in 2025 (+16% vs 2024). |
Topics and scope
- Virus-based gene therapy research (28% of indexed topics)
- RNA Interference and Gene Delivery (17% of indexed topics)
- CRISPR and Genetic Engineering (8% of indexed topics)
- CAR-T cell therapy research (7% of indexed topics)
- Viral Infectious Diseases and Gene Expression in Insects (6% of indexed topics)
- Immunotherapy and Immune Responses (4% of indexed topics)
Biochemistry, Genetics and Molecular Biology journalsMolecular Biology journalsGenetics journals
Similar journals — faster or cheaper, side by side
Journals publishing on the most similar topics (OpenAlex), ordered by similarity. Only 2025 figures are compared with the 2025 median of Gene Therapy, 169 days.
| Paid APC median | DOAJ | MEDLINE | |||
|---|---|---|---|---|---|
| Molecular Therapy | 146 (2025, n = 558) | ≈$4,500 | $4,012 (6 payments) | No | Yes |
| Molecular Therapy — Methods & Clinical Development | 159 (2025, n = 191) | $3,900 | $3,865 (8 payments) | Yes | No |
| Current Gene Therapy | 98 (2025, n = 71) | — | — | No | Yes |
| Cancer Gene Therapy | 146 (2025, n = 116) | ≈$4,990 | — | No | Yes |
| The Journal of Gene Medicine | 96 (2025, n = 59) | ≈$4,480 | — | No | Yes |
| Molecular Therapy Oncology | 165 (2025, n = 116) | $3,900 | — | Yes | No |
| Molecular Therapy — Nucleic Acids | 171 (2025, n = 231) | $3,900 | $3,685 (15 payments) | Yes | No |
| Nature Biomedical Engineering | 482 (2025, n = 202) | ≈$12,690 | — | No | Yes |
No journals match these filters.
Frequently asked questions
How long does Gene Therapy take to accept a paper?
Half of the articles Gene Therapy accepted in 2025 were accepted within 169 days of submission (n = 71); the middle half took 134–251 days. Based on dates in PubMed for accepted articles only.
How long after acceptance are Gene Therapy articles published online?
Half of the articles accepted in 2025 appeared online within 14 days of acceptance (n = 71).
Does Gene Therapy charge an article processing charge (APC)?
Listed APC: about $3,790 (as reported by OpenAlex).
Sources and method
Journal identity: ISSN-L 0969-7128; NLM ID 9421525; OpenAlex record. Speed figures use 71 articles accepted in 2025 with valid dates; excluded records for that year: none.
Spotted a problem with this journal's data, or are you the publisher? Report a correction or email rafiq@gradsummit.com. Verified errors are corrected within five business days.
Get the free Journal Submission Go/No-Go Checklist
The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.
Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.